What are the typical symptoms and recommended management strategies for congestive heart failure?

Symptoms and Management of Congestive Heart Failure

Congestive heart failure presents with dyspnea, peripheral edema, orthopnea, paroxysmal nocturnal dyspnea, and bendopnea, and should be managed with ACE inhibitors as first-line therapy combined with beta-blockers and diuretics for symptomatic relief, with mineralocorticoid receptor antagonists added for persistent symptoms. 1, 2

Clinical Presentation

The typical symptoms of CHF include:

• Dyspnea (shortness of breath) from pulmonary congestion
• Peripheral edema in the lower extremities
• Orthopnea (difficulty breathing when lying flat)
• Paroxysmal nocturnal dyspnea (sudden nighttime breathlessness)
• Bendopnea (shortness of breath when bending forward)
• Fatigue and decreased exercise tolerance
• Constitutional symptoms including nausea and lack of appetite 3, 4

Key physical examination findings to assess at each encounter include jugular venous distention, evidence of pulmonary congestion, peripheral edema, and vital signs to guide diuretic adjustment 5.

Pharmacological Management Algorithm

Step 1: First-Line Therapy for HFrEF (Reduced Ejection Fraction)

ACE inhibitors are the cornerstone of treatment and should be initiated in all patients with reduced left ventricular systolic function unless contraindicated 1, 2.

ACE inhibitor initiation protocol:

• Review and potentially reduce diuretics 24 hours before starting
• Start with low dose, preferably in the evening when supine to minimize hypotension
• Titrate up to maintenance doses proven effective in large trials
• Monitor blood pressure, renal function, and electrolytes at 1-2 weeks after each dose increment, then at 3 months, then every 6 months
• Avoid NSAIDs and potassium-sparing diuretics during initiation
• Stop if renal function deteriorates substantially 1

Step 2: Add Beta-Blockers

Beta-blockers are recommended for all patients with stable HFrEF (NYHA class II-IV) in addition to ACE inhibitors to reduce hospitalization and death 1, 6, 2.

Beta-blocker initiation protocol:

• Patient must be relatively stable without need for IV inotropes or marked fluid retention
• Start with very low dose and double every 1-2 weeks if tolerated
• Monitor for worsening heart failure, hypotension, and bradycardia
• If symptoms worsen, increase diuretics or ACE inhibitor dose first before reducing beta-blocker
• Most patients can be managed as outpatients 6

Step 3: Diuretics for Symptomatic Relief

Diuretics are essential when fluid overload is present manifesting as pulmonary congestion or peripheral edema 1, 2.

Diuretic management strategy:

• Initial treatment: Loop diuretics or thiazides, always with an ACE inhibitor
• If GFR <30 mL/min, avoid thiazides except synergistically with loop diuretics
• For insufficient response: Increase diuretic dose, combine loop diuretics with thiazides, or administer loop diuretics twice daily
• For severe refractory CHF: Add metolazone with frequent monitoring of creatinine and electrolytes 1

Step 4: Mineralocorticoid Receptor Antagonists (MRAs)

Add an MRA (spironolactone) for patients who remain symptomatic despite ACE inhibitor and beta-blocker therapy to reduce hospitalization and death 1, 2.

Potassium-sparing diuretic monitoring:

• Use only if hypokalaemia persists after ACE inhibitor and diuretic initiation
• Check serum potassium and creatinine after 5-7 days
• Recheck every 5-7 days until values are stable, then every 3-6 months 1, 6

Step 5: Advanced Therapies for Persistent Symptoms

For ambulatory patients with HFrEF who remain symptomatic on optimal therapy, sacubitril/valsartan should replace the ACE inhibitor to further reduce hospitalization and death 2.

Non-Pharmacological Management

Patient education and lifestyle modifications are critical:

• Explain what heart failure is and why symptoms occur
• Teach daily self-weighing to monitor fluid retention
• Sodium restriction in patients with severe heart failure
• Avoid excessive fluid intake in severe HF
• Avoid excessive alcohol
• Smoking cessation with nicotine replacement if needed 1

Exercise recommendations:

• Rest is NOT encouraged in stable conditions
• Maintain daily physical and leisure activities to prevent muscle deconditioning
• Exercise training programs recommended for stable NYHA II-III patients 1

Critical Pitfalls to Avoid

1. Do not use diltiazem or verapamil in HFrEF - they increase risk of worsening heart failure and hospitalization 2

2. Avoid triple renin-angiotensin-aldosterone system blockade (ACE inhibitor + ARB + MRA) due to increased risk of renal dysfunction and hyperkalemia 2

3. Do not withhold beta-blockers in stable patients - they provide mortality benefit across NYHA classes II-IV 1, 6

4. Monitor electrolytes closely when combining diuretics with ACE inhibitors and MRAs to prevent dangerous hyperkalemia 1, 6

Heart Failure with Preserved Ejection Fraction (HFpEF)

For HFpEF (LVEF ≥50%), SGLT2 inhibitors are now recommended across the entire ejection fraction spectrum 2, 7. Management also includes:

• Diuretics for congestion
• Treatment of hypertension
• Management of contributing comorbidities (CAD, diabetes, obesity)
• Consider sacubitril/valsartan, though benefit is greater with LVEF closer to 50% 8

The evidence base for HFpEF management has evolved significantly, with SGLT2 inhibitors representing a major therapeutic advance for this previously difficult-to-treat population 7.